Zydus receives final approval from US FDA for Bortezomib for injection

Zydus Lifesciences has received final approval from the US Food and Drug Administration (FDA) to market Bortezomib for injection, 3.5 mg/vial, single-dose vial, a company statement notified.

Bortezomib for injection is used to treat certain types of cancer such as multiple myeloma and mantle cell lymphoma. The medication works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira, the statement added.